Background: Waist circumference (WC) is frequently measured in clinical and research settings. Although measurement protocols may differ considerably, a single set of sex-specific cut-points are typically used to denote elevated risk. The purpose of this study was to determine whether the appropriate WC thresholds for identifying cardiometabolic risk vary according to anatomical measurement site. Methods: WC was measured at four common sites in 520 community-dwelling adults (20-66 years): superior border of the iliac crest, midpoint between the iliac crest and the lowest rib, umbilicus and minimal waist. Resting blood pressures and fasting levels of total cholesterol, high-density lipoprotein-cholesterol, triglycerides and glucose were measured. The sensitivity and specificity of current WC thresholds (M: 4102 cm/40 inch; W: 488 cm/35 inch) for detecting abnormal risk factor levels were calculated for each WC measurement site, and receiver operating characteristic (ROC) curves were used to select optimal thresholds for identifying individuals with risk factor clustering (X2 risk factors). Results: The area under the ROC curve for WC measured at each anatomical site was similar for each risk factor and for the presence of risk factor clustering. However, WC 488/102 cm at the umbilicus showed the greatest sensitivity for all outcomes, whereas measurements at the minimal waist had the best specificity in this sample. The sensitivity of WC 488/102 cm for detecting X2 risk factors ranged from 75 to 89% in women and from 48 to 59% in men, and specificity ranged from 52 to 79% in women and from 77 to 88% in men, across measurement sites. Conclusions: At present, recommended WC thresholds may not have the same clinical utility at all anatomical locations of WC measurement.
Introduction
The measurement of waist circumference (WC) is widely advocated as a simple anthropometric indicator of metabolic and cardiovascular disease risk (World Health Organization, 2000a) and is an integral part of clinical practice guidelines for the identification and treatment of overweight and obesity in several countries, including the United States (NIH Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults, 1998), Canada (Lau et al., 2007) and Australia (National Health and Medicine Research Council, 2003 ). Yet, despite the frequent use of WC measurements, there remains no universally accepted measurement protocol. A survey of the published literature indicates that measurements above the iliac crest, at the midpoint between the iliac crest and lowest rib, at the level of the umbilicus and at the minimal waist are all commonly used in clinical and research settings (Wang et al., 2003; Ross et al., 2008) .
Abdominal obesity is generally classified using dichotomous WC thresholds. The most frequently used cut-points (M: 4102 cm/40 in; W: 488 cm/35 in) were derived from WC measurements taken mid-way between the lowest rib and the iliac crest, to correspond with a body mass index (BMI) of 30 kg/m 2 (Lean et al., 1995) , but are not based on the direct relationship between WC and health risk. We have previously documented significant differences in the prevalence of abdominal obesity with WC measures taken at different anatomical locations (Mason and Katzmarzyk, 2009b) , as well as modest differences in the prevalence of metabolic syndrome (Mason and Katzmarzyk, 2009a) ; however, the potential value of anatomic site-specific WC cut-points in predicting cardiometabolic risk remains unclear. Accordingly, the purpose of this study was to identify optimal WC thresholds for the prediction of cardiometabolic risk across four commonly used anatomical sites of WC measurement.
Participants and Methods
Sample A convenience sample of healthy volunteers (208 men; 312 women) 20-66 years of age were recruited from the local community using posters and advertisements. Pregnant women and subjects currently undergoing treatment for any systemic illness (for example, cancer, human immunodeficiency virus/AIDS) that could influence WC were not eligible to participate. The study protocol was approved by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board. All participants provided written informed consent before participation.
Measures
Anthropometry. Participants wore light clothing and no shoes for measurements of height and weight. Height was measured to the nearest 0.1 cm and weight was measured to the nearest 0.1 kg using a stadiometer and standard digital scale (Tanita HD-351, Arlington Heights, IL, USA), respectively. WC was measured using a flexible, tension-sensitive, non-stretching tape measure (Gulick II, County Technology, Gay Mills, WI, USA) placed directly on the skin. Participants stood relaxed with legs parallel and shoulder-width apart; arms were folded comfortably across the chest. Measurements were taken at the end of normal expiration with special attention paid to ensure the tape lay perpendicular to the long axis of the body and parallel to the floor. A series of four measurements were taken at the following anatomical locations by a single, trained researcher: immediately above the superior border of the iliac crest, midpoint between the superior border of iliac crest and the lowest rib, the umbilicus and the minimal waist.
Cardiometabolic risk factors. Resting blood pressure was measured using an automated monitor (BpTRU model BPM-100; VSM MedTech Ltd, Vancouver, BC, Canada). After 5 min of rest, six serial measurements were taken at 1-min intervals. The last five readings were averaged and recorded. Blood samples were taken in the morning after an overnight fast of approximately 12 h. Samples were drawn using a single capillary finger-stick sample and analyzed (Cholestech LDX, Hayward, CA, USA) for concentrations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides and glucose. The Cholestech LDX system has been validated against reference laboratories and performed well (Carey et al., 2006; Dale et al., 2008) . Study participants provided a list of physician prescribed medications and indicated if they were being treated for high blood pressure, dyslipidemia or type 2 diabetes/elevated blood glucose.
Owing to a non-normal distribution, plasma triglyceride values were log-transformed before further analysis. Risk variables were dichotomized according to the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) clinical criteria for diagnosis of the metabolic syndrome (Grundy et al., 2005) : high blood pressure (systolic blood pressure X130 mm Hg or diastolic blood pressure X85 mm Hg or drug treatment for hypertension), elevated plasma triglycerides (X1.7 mmol/l or drug treatment for elevated triglycerides), low HDL-cholesterol (M: o1.03 mmol/l; F: o1.3 mmol/l) and elevated fasting blood glucose (X5.6 mmol/l or drug treatment for type 2 diabetes or elevated glucose). For the purpose of this study, elevated cardiometabolic risk was operationally defined as the presence of two or more (X2) of: high blood pressure, elevated triglycerides, low HDL-cholesterol and/or elevated fasting blood glucose.
Statistical analysis. Pearson correlation coefficients were calculated between each WC site and were used to summarize the relationships between WC and cardiometabolic risk factors (blood pressure, HDL-cholesterol, triglycerides, blood glucose) for each WC measurement site. The correlation analysis excluded those participants who indicated that they were taking medications for hypertension (n ¼ 35), dyslipidemia (n ¼ 9) or diabetes (n ¼ 4).
The sensitivity and specificity of current WC thresholds (M: 4102 cm/40 inch; W: 488 cm/35 inch) for detecting abnormal risk factor levels and risk factor clustering (X2 risk factors) were calculated for each of the four locations of WC measurement. Receiver Operating Characteristic (ROC) curves were used to select the optimal anthropometric thresholds that identified individuals with abnormal risk factor levels and risk factor clustering. As the area under the curve is considered a measure of the utility of WC and represents the trade-off between the correct identification of high-risk individuals (sensitivity) and the correct identification of low-risk individuals (specificity), the optimal threshold was considered to be the point of convergence between sensitivity and specificity. WC values one step above the point at which specificity exceeded sensitivity were selected and rounded to the nearest centimeter (Brownie et al., 1986) .
Data management and analysis was conducted using SAS software and procedures version 9.1 (SAS Institute Inc, Cary, NC, USA). SPSS version 17.0 (Chicago, IL, USA) was used to construct the ROC curves.
Results
Baseline characteristics (mean, s.d.) of the sample are presented in Table 1 . The sample was predominantly white (95%) but ranged in age (20-66 years) and BMI (18.6-49.2 kg/m 2 ). Exclusion of non-white participants made no meaningful change to the study's results. In both sexes, the highest mean WC values were measured at the umbilicus and the smallest at the minimal waist, with a mean range of 2.5 and 8.6 cm across sites in men and women, respectively. These differences translated into substantially more men (34 vs 23%) and more women (55 vs 31%) meeting the criteria for abdominal obesity when WC was measured at the umbilicus compared with the minimal waist.
WC measurements taken at all four sites were highly correlated with each other in both men and women, ranging from 0.95 to 0.99 (all Po0.001). WC was inversely associated with HDL-cholesterol (r ¼ À0.28 to À0.39) and positively correlated with all other risk variables (systolic blood pressure: r ¼ 0.38-0.44; diastolic blood pressure: r ¼ 0.26-0.48; triglycerides: r ¼ 0.31-0.42; glucose: r ¼ 0.21-0.39). The magnitude of the correlations between cardiometabolic risk factors and WC at each site are not significantly different from one another in this sample (Mason and Katzmarzyk, 2009a) .
The area under the curve for WC measured at each anatomical site was similar for each risk factor examined and for the presence of risk factor clustering in both men and women (Table 2 ). The largest difference between area under the curves across sites for any risk variable was 0.088. Although not tested statistically, the sensitivity and specificity of high WC (488/102 cm) for detecting elevated cardiometabolic risk varied across measurement sites. In general, WC demonstrated greater sensitivity but less specificity for detecting risk factor clustering in women compared with men. For example, the sensitivity for WC at detecting X2 risk factors ranged from 75 to 89% in women and from 48 to 59% in men, and specificity ranged from 52 to 79% in women and from 77 to 88% in men, across measurement sites. In both sexes, WC at the umbilicus showed greater sensitivity but less specificity for all outcomes. In contrast, measurements at the minimal waist had less sensitivity but greater specificity.
Optimal WC thresholds and their corresponding sensitivity and specificity for predicting the presence of X2 cardiometabolic risk factors in men and women are presented in Table 3 . In men, the optimal cut-off was 100 cm at the umbilicus, iliac crest and midpoint, but lower (97 cm) at the minimal waist. In women, optimal cut-offs ranged from 87 cm at the minimal waist to 95 cm at the umbilicus. Applying these cut-offs resulted in similar degrees of sensitivity and specificity for the detection of cardiometabolic risk clustering for all WC sites. Elevated risk factors defined as: high blood pressure (systolic: X130 mm Hg or diastolic: X85 mm Hg), high plasma triglycerides (X1.7 mmol/l), low HDL-C (M: o1.03 mmol/l; F: o1.3 mmol/l) and high blood glucose (X5.6 mmol/l). Individuals taking prescribed medication for hypertension, dyslipidemia or type 2 diabetes were considered to be meeting the corresponding risk criteria.
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Discussion
The results of this study indicate that the anatomical location of WC measurement will influence the sensitivity and specificity of WC thresholds 488/102 cm for detecting elevated cardiometabolic risk. On the basis of our estimates, WC thresholds of 4102/88 cm are most sensitive but also least specific for detecting abnormal risk factor levels at the umbilicus compared with other measurement sites. In contrast, measurements at the minimal waist are most specific but are somewhat less sensitive. As a consequence of these differences, the identification of optimal WC thresholds for identifying risk factor clustering varied according to the anatomical site of measurement, more so in women than men. In men, the optimal cut-off was the same at the umbilicus, iliac crest and midpoint. In women, the difference between the optimal cut-point at the umbilicus by comparison with the minimal waist was 8 cm. Thus, uniformly applying the same clinical cut-points irrespective of the WC measurement protocol will not yield the same ability to identify patients with elevated cardiometabolic risk.
A similar pattern of association between WC and outcomes including cardiovascular disease, diabetes and mortality, irrespective of WC measurement protocol, has been documented in a comprehensive review of prospective studies (Ross et al., 2008) . However, the present analysis highlights the potential impact of measurement site on the clinical utility of WC for obesity-related risk stratification. For example, our data suggest that individuals who have their WC measured at the minimal waist may be less likely to be considered at-risk and undergo further assessment of comorbid conditions than if WC measurements were made at the umbilicus, iliac crest or midpoint. Abbreviations: AUC, area under the receiver operating characteristic curve; WC, waist circumference. Sensitivity ¼ true positive/(true positive þ false negative) Â 100. Specificity ¼ true negative/ (true negative þ false positive) Â 100. Risk factors included: high blood pressure (systolic: X130 mm Hg or diastolic: X85 mm Hg), high plasma triglycerides (X1.7 mmol/l), low high-density lipoprotein cholesterol (M: o1.03 mmol/l; F: o1.3 mmol/l), and high blood glucose (X5.6 mmol/l). Individuals taking prescribed medication for hypertension, dyslipidemia or type 2 diabetes were considered to be meeting the corresponding risk criteria.
Overall, the optimal thresholds identified for men in this sample at all measurement sites were slightly lower than the currently recommended threshold of 102 cm. In contrast, the optimal thresholds for women in this sample were all higher than the current recommendation of 88 cm. Alternate WC cut-points are proposed for specific racial/ethnic groups (Alberti et al., 2006; Lau et al., 2007) and for different BMI categories (Ardern et al., 2004; Bray, 2004 ) but these have not been widely validated. The practicality of having a wide array of thresholds specific to particular ethnic groups, BMI categories and measurement protocols deserves some critical consideration as this could compromise the feasibility and acceptability of routine WC measurement in clinical settings. Nevertheless, efforts to standardize the measurement of WC for the assessment and treatment of obesity may be warranted given the value of early intervention for the prevention of risk factor progression and the development of related outcomes.
We have previously shown that neither the intra-nor inter-rater reliability of WC varies meaningfully across measurement sites (Mason and Katzmarzyk, 2009b) , nor does the reliability of these measures vary according to BMI status in persons with BMI values predominantly in the range of 20-35 kg/m 2 (Mason and Katzmarzyk, 2009b) . All measurements in this study were made by a trained anthropometrist. Although familiarity and practice in locating specific physical landmarks is likely to yield more consistent WC measurements, a modest amount of training has been shown to be effective in this regard (Sebo et al., 2008) . In light of the ease and low cost of measuring WC, the superior sensitivity of measurements taken at the umbilicus could be considered a benefit relative to other sites. On the other hand, the reliance on internal (bony) landmarks required for measurements at the iliac crest and midpoint may be of greater practical benefit as these will remain more stable during periods of weight gain or loss.
This study has several strengths and limitations that warrant discussion. First, the study design was crosssectional; therefore, the site-specific WC thresholds identified from this analysis are based on their association with concurrent comorbid conditions rather than a demonstrated ability to predict risk factor development or overt disease. Given that WC is commonly used for screening purposes, variation in the sensitivity and specificity of different WC sites for detecting cardiometabolic risk factors is relevant to current clinical practice and to the growing use of risk assessment batteries that incorporate measurement of WC (NIH Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults, 1998; National Health and Medicine Research Council, 2003; Lau et al., 2007) . The results of this study cannot support the use of one measurement protocol over another; however, the results highlight the importance of understanding the differences across measurement sites and the need to better standardize measurement protocols between countries.
The primarily Caucasian sample also represents a limitation of the study, as it is clear that the nature of the relationship between abdominal fat distribution and health risk varies between some populations (Lear et al., 2003; WHO Expert Consultation, 2004; Razak et al., 2005) , and differences according to ethnicity could not be examined here. In addition, age, general health status and other factors could alter the sensitivity and specificity of WC measures at different anatomical sites and therefore impact the selection of optimal thresholds. Thus, examining the predictive nature of WC measurement across different sites warrants investigation in diverse populations, particularly among those for whom alternative cut-points are recommended (World Health Organization, 2000b) .
The overall prevalence of cardiometabolic risk factors in this sample is similar to the most recent population estimates for Canada (Reeder et al., 1997; Ardern and Janssen, 2007) . However, in the absence of any contemporary population-level data, it is difficult to estimate to what degree this sample may be affected by a 'healthy subject' bias. The prevalence of risk factors considered in this analysis may have also been influenced by the reliance on self-reported physician-prescribed medications and point-ofcare blood analysis that was not confirmed in secondary laboratory tests. Furthermore, the use of serial automated blood pressure measurements have been shown to result in lower measurements (À8/7 mm Hg) as compared with ausculatory methods (Campbell et al., 2005) , but are generally similar to mean awake 24-h ambulatory blood pressure readings (Myers et al., 2008) .
Given that the determination of ROC curves are influenced by the prevalence of the exposure and its association with the outcome in the study sample (Hayes et al., 2006) , future validation of the site-specific WC thresholds identified in this study would be useful in confirming the extent to which the anatomical site of measurement influences the utility and interpretation of WC data. Recognizing potential differences across sites in this regard is an important and timely issue given the growing recognition of abdominal obesity as a risk factor for adverse health outcomes and its increasingly widespread use for risk stratification.
Overall, the results of this study confirm the utility of WC in predicting cardiometabolic risk, irrespective of measurement site. When considered as a continuous variable, WC exhibits a similar association with metabolic risk factors across several common measurement sites. However, the results also highlight the influence of measurement protocol on the utility of WC for the identification of obesity-related health risk. Commonly used protocols should therefore not be considered interchangeable when cut-points such as 88 or 102 cm are applied for the purpose of risk stratification. Efforts to standardize the anatomic location of WC measurement in clinical practice as well as research settings will facilitate the comparison of results and should be a priority in moving toward a universal approach to the assessment of cardiometabolic risk.
